Mechanistic insights into Old English plants

Jasminum humile inhibits calcineurin. Credit: Geoffrey Kite

Often lacking in natural product drug discovery are ‘mechanistic insights’; that is, insights into the events at the molecular level that are behind any effects that plant compounds have on cells or organisms. With this in mind, Tom Prescott screened 250 Old English plants from the Queen’s Garden at Kew, to search for compounds that inhibit the human enzyme calcineurin. The results have been published in the Journal of Ethnopharmacology.

Calcineurin plays an important role in regulating human T-cell activation in the immune response, and inhibition of this process can be beneficial in certain auto-immune diseases.

Nepeta cataria and Teucrium chamaedrys showed initial promise but the compounds responsible (phenylpropanoid glycosides) were only strongly active against the basal, un-activated form of the enzyme.

Jasminum humile was found to be more promising as the ethanol extract inhibited both isolated human calcineurin enzyme and calcineurin-dependent gene expression in yeast cells. This demonstrated that plants do indeed produce compounds that directly inhibit .

More information: Prescott, T. A. K., et al. (2011). Direct inhibition of calcineurin by caffeoyl phenylethanoid glycosides from Teucrium chamaedrys and Nepeta cataria. Journal of Ethnopharmacology 137: 1306–1310.

Prescott, T. A. K., et al. (2012). Inhibition of human calcineurin and yeast calcineurin-dependent gene expression by Jasminum humile leaf and root extracts. Journal of Ethnopharmacology 140: 293-297.

add to favorites email to friend print save as pdf

Related Stories

Time to stop giving toxic drugs to kidney transplant patients?

Sep 22, 2011

Patients who receive kidney transplants must take lifelong medications that, while preventing organ rejection, can also compromise other aspects of health. Immunosuppresive drugs called calcineurin inhibitors protect transplanted ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments